Biotech partnerships
Recursion cuts Tempus data fees and licenses its TxFM RNA model for $12 million
An amendment extends the Tempus master deal to six years, removes convenience termination, and resets anniversary license fees to $14 million, while a separate two-year oncology TxFM license brings $12 million from Tempus.